Our Team
Our Team
Team Members
Fotis completed his MD/PhD at the University of Cambridge in the UK, working with Tony Green on mapping 20q deletions associated with pre-leukemias. He then spent two (in his own words, “unforgettable”) years in Jerusalem working with Dina Ben Yehuda as a Golda Meir Fellow on mechanisms underlying CML clonal evolution. After residency at Brigham and Women’s Hospital in Boston and oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York, he joined Nobel prize laureate Harold Varmus’ group at MSK with the goal to help generate a RAS-driven model for multiple myeloma. In 2010, he became an Assistant Professor and later a tenured Associate Professor at UW-Madison. From 2019 to 2025, Fotis served as an Associate and Full Professor and Robert Shillman Scholar in Cancer Research at the University of California San Diego Moores Cancer Center. In 2025, he became the Robert E. and Emily H. King Professor and Director of the Multiple Myeloma Program at Rush MD Anderson Cancer Center in Chicago IL. Fotis is an elected member of the American Society for Clinical Investigation (ASCI).
Thanos grew up in Greece, where he also attended Medical School. His growing passion during medical school was to pursue a physician-scientist career in Cancer Immunology. After graduating with an MD from Greece, he moved to the US and completed his PhD in Cancer Immunotherapy in the Asimakopoulos Lab at UW-Madison. He continued his scientific training as a postdoctoral scholar at UC-San Diego, where the Asimakopoulos Lab relocated and as of June 2023, started his clinical training in Internal Medicine at the Ohio State University with the goal of pursuing a Hematology/Oncology fellowship afterwards. His graduate and postdoctoral work focused on pathways that promote tumor immunogenicity and enhance tumor vaccine efficacy by shedding light on a relatively understudied facet of intratumoral immune regulation, the cross-talk of myeloid cells with matrix in the tumor microenvironment. He worked towards developing novel strategies for transforming an immunologically “cold” tumor into “hot” by harnessing “matrikines” as immunological adjuvants.
Alex graduated with a B.S. In Molecular Biology from UW-Madison in 2020, before working in Dr. Fotis Asimakopoulos’ laboratory studying the role of extracellular stromal remodelling on the immune microenvironment of tumors at UCSD. He joined the MSTP (MD/PhD) at Stony Brook in 2022 and is now completing his dissertation research in the lab of Dr. Peter Westcot at CSHL.
Kevin Lynch, MB, BS. is inspired by the opportunity to develop transformative medicines for patients.
He has lived and worked in Australia, Asia, UK and Switzerland, operating in both small, start-up environments as well as large, multi-nationals.
Kevin was Chief Medical Expert during Antengene’s formative years and then through a period of extreme growth as Chief Medical Officer. He supervised their broad clinical program with Xpovio (Selinexor) in Asia-Pacific, as well as an extensive first-in-human early development program.
During over 11 years at Celgene Kevin was closely involved in the successful clinical development and registration of Revlimid (lenalidomide), Pomalyst (pomalidomide), Vidaza (azacitidine), Onureg (oral azacitidine) and Idhifa (enasidinib).
During his 10 years with Novartis, as one of the inaugural Oncology Medical Directors for the company, he played a key role in the development and approvals of multiple transformative drugs including Glivec (imatinib), Tasigna (nilotinib), Zometa (zoledronic acid), Femara (letrozole) and Exjade (deferasirox).
Kevin graduated B Med Sci and MB, BS from the University of Tasmania in Australia. His post-graduate training in Pharmaceutical Medicine was completed in the UK, where he gained his Fellowship of the Faculty of Pharmaceutical Medicine.
Peter Greaney, PhD. is a global deal-maker and is passionate about advancing innovative science for the benefit of patients.
Peter has international experience in building successful biotech companies. He has been responsible for the successful execution of numerous business development deals in his career and has experience in a wide array of deal structures. He is experienced in seeking new business opportunities, leading negotiations, and managing research collaborations.
At ADC Therapeutics, Peter was the Head of Corporate Development and played an integral role transforming the company from a private R&D biotech to a NYSE listed public biotech with a commercial therapeutic product. Prior to ADC Therapeutics, Peter held medical and business positions of increasing responsibility at Celgene in Switzerland and the United States. He held roles in Business Development, Strategy & Operations, Market Research & Business Intelligence, Medical Affairs, and Medical Development.
Prior to Celgene, Peter was a Preclinical Senior Scientist at Apoxis, S.A. in Switzerland and an intern scientist at Servier, Paris.
Peter graduated with a Bachelor of Science in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham (supported by Servier).
Gertjan Bartlema, thrives on building teams and creating collaborative impact. He is a pragmatic and authentic leader with broad operational biotech experience.
Gertjan was the CEO of VICO Therapeutics BV a privately held Netherlands based company focused on antisense oligonucleotide-based RNA modulating therapeutics for rare CNS diseases.
During his 20+ years global biotech career he was part of emerging organizations and new capability building, including healthcare big data/real-world data and marketing & sales excellence capabilities. During his 12 years at Celgene (US and Switzerland), he was part of the European management team, the corporate business development team that acquired Abraxis and the information knowledge utilization team that established an industry leading network of real-world data and technology partnerships including COTA, Inc., Flatiron Health, and GNS Healthcare and strategic partnerships with IBM Watson, Health2047, and M2Gen.
Other roles he held during his career include Strategy, Marketing & Sales Excellence, Business Planning and Financial Planning & Analysis. He started his biotech career at Amgen Europe based in Lucerne, Switzerland. Over a nine year period at Amgen was based in Thousand Oaks, CA and Switzerland.
Gertjan holds a Masters in Economics from Maastricht University, the Netherlands and was an ERASMUS student at Bern University, Switzerland. He holds a dual Dutch and Swiss citizenship. He lives with his family in Switzerland.